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strategy reduces the risk of overestimating adherence. For prescriptions extending 
beyond the end of the analysis period, days’ supply is truncated at the end of the 
period. Patients in each study sample are stratified into 5 categories based on their 
adherence score: 1–19%, 20–39%, 40–59%, 60–79%, or 80–100 %. Results: High level 
of medication adherence was associated with lower hospitalization and exacerba-
tion rates. ConClusions: Increased drug utilization can provide a net economic 
return when it is driven by improved adherence.
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objeCtives: It is a common practice in outcomes research studies to examine 
several co-morbidities over two or more cohorts to develop some intuition about 
the health status of each group. It is also a common practice in claims data to record 
the co-morbid condition as a binary variable (i.e., absence or presence of the co-
morbidity). If an investigator is interested in studying the absence or presence of 
10 co-morbidities, he or she will have to consider 210= 1024 possible co-morbidity 
patterns, a seemingly daunting task. The common current practice is to construct 
summary tables and examine them to understand cohort co-morbidity patterns. 
Even with this summarization, it is difficult to deduce what the composition is for 
the cohort over all co-morbidities simultaneously. Once again, this can be a daunt-
ing task. The objective of this research is to develop a means of summarizing these 
rich and somewhat complex data to enhance clinical decision making. Methods: 
Graphical approaches for the summarization of data enable geometry, scaling, shad-
ing, and or color to describe such “high dimensional” data. The author will introduce 
a novel means of plotting the co-morbid conditions that will afford investigators 
the ability to study patterns of co-morbidities simultaneously and understand the 
relative frequencies of their occurrence in one display. Results: The use of a novel 
graphical procedure (a Saturn plot) allows an investigator to examine co-morbidity 
patterns readily when the number of binary co-morbidities is 10 without having to 
resort to poring over several tables or one large table partitioned into smaller ones 
based on co-morbidities. ConClusions: A newly developed graphical data sum-
mary called a Saturn plot allows investigators to indentify the relative frequency of 
various subgroups (as defined by their co-morbidity pattern) within a cohort without 
the need to study large sets of tables.
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objeCtives: In December 2011 the Danish Government issued a new plan of action 
for chronic disease management in the Danish counties and DKK 100 million were 
granted to set up new positions as case managers to help vulnerable elderly patients. 
No precise job description was provided, however, and the Danish counties request 
evidence for the effect of case management (CM). The aim of this study was to 1) 
design a job description for a case manager, and 2) design a RCT evaluating conse-
quences and costs of providing local CM to patients with COPD. Methods: By use 
of the UK Medical Research Councils (MRC) framework for development of complex 
interventions, the design of the case manager job description and the RCT was 
determined through a systematic literature review, interviews with key persons and 
discussions in a specialist-comprised steering group. Results: CM was designed to 
encompass coordination of care, facilitation of relevant health- and social services 
and promotion of patient self-care through advocacy and education. The RCT was 
powered to detect the effect of CM on hospital admissions. Secondary measures 
include mortality, quality of life, self-care and cost-effectiveness of CM versus usual 
care. 150 COPD patients are randomized into two groups after referral to pulmo-
nary rehabilitation at the local rehabilitation center in Aalborg County, Denmark. 
The control group will receive usual care, whereas the interventional group will 
receive CM besides their usual care. Each patient is followed for 12 months. The 
questionnaires SF-12, EQ-5D, Sct. George-Respiratory-Questionnaire (SG-RQ) and 
The Patient-Activation-Measure (PAM-13) are completed at baseline and 12 months. 
Prospectively collected data from national population-based medical registries are 
used to estimate events and resource usage. ConClusions: The study is expected 
to provide further insight to the future organization of CM, and if being cost-effec-
tive, the intervention could be applied to comparable health care settings.
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objeCtives: Indirect comparisons are often based on binary outcomes (e.g. relapse / 
remission) or continuous outcomes. In these cases logistic or linear models are applied 
to make the indirect comparisons. However, sometimes datasets contain multino-
mial outcomes, such as ‘complete’, ‘partial’ and ‘no’ response in oncology, that need 
to be indirectly compared. With multinomial data, different indirect comparisons 
methods may be required to answer different research questions. Our goal was to 
identify and qualitatively compare the different techniques that have been used to 
model multinomial data in an indirect comparison framework. Methods: A system-
atic review of the PubMed database was conducted to identify different methods for 
handling multinomial data in a meta-analysis. Key words included ‘meta-analysis’, 
‘ordinal’, ‘ordered’, ‘multinomial’ and ‘proportional odds’, in various combinations. 
Models were qualitatively compared according to their assumptions, flexibility and 
complexity. Results: The systematic review identified three methods: a proportional 
odds model, an ordered logistic model, and a multinomial model. The proportional 
lowest threshold where the effect of treatment is significant allows the selection 
of patients that could be mostly benefited with the treatment, the selection of the 
threshold with the minimum p-value will reflect the higher difference between 
treatments.
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objeCtives: There are a number of instruments to describe severity and progres-
sion of multiple sclerosis, which are increasingly used as endpoints to assess the 
effectiveness of therapeutic interventions. We examined to what extent the psy-
chometric properties of the two accepted instruments - EDSS and MSFC – meet the 
methodological standards and what value they have in clinical trials. Methods: We 
conducted a systematic literature search in relevant databases [MEDLINE (PubMed), 
ISI Web of Science, EMBASE, PsycINFO & PSYNDEX, CINAHL] yielding 3,860 results. 
The identification of relevant full-text publications was conducted using abstract 
and then full-text reviews. Results: For evaluation of psychometric properties 
(validity, reliability, sensitivity of change) of EDSS and MSFC, 120 relevant full-text 
publications were identified, 54 of them assessed the EDSS, 26 the MSFC and 40 
included both instruments. The EDSS has some documented weaknesses in reli-
ability and sensitivity to change. For the MSFC, the main limitations are the learn-
ing effects and the z-scores method used to calculate the total score. However, the 
methodological criterion of validity applies sufficiently for both instruments. For 
use in clinical studies, we found that the EDSS has been preferred as a primary and 
secondary outcome measure in recent studies (50 EDSS, 9 MSFC). ConClusions: 
Recognizing their strengths and weaknesses, both EDSS and MSFC are suitable 
to detect the effectiveness of clinical interventions and to monitor the disease 
progress. Almost all publications identify the EDSS as the most widely used tool to 
measure disease outcomes in clinical trials. Despite some limitations, both instru-
ments are accepted to generate “hard endpoints”. In no publication, EDSS or MSFC 
are discussed as surrogate parameters. A great advantage of the EDSS is the inter-
national acceptance (e.g. by EMA) as a primary endpoint in clinical trials and its 
broad use in trials, enabling cross-study comparisons.
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objeCtives: To evaluate the impact of medication adherence on health care utili-
zation and costs of the patients with asthma in Hungary. Methods: The authors 
conducted a retrospective observation of the patients continuously enrolled in med-
ical and prescription benefit plans from July 2007 to June 2012. The study is based 
on patient attendance data of Hungarian National Health Insurance Fund -NHIFA. 
The accessible resource uniquely contains the detailed provision data (medicine, 
out- and inpatient services) about the whole 10 millions Hungarian populations. 
Inclusion criterion for the patients was at least one diagnosis of asthma in inpa-
tient or outpatient care (ICD code J45) and at least one relevant asthma therapy 
prescription in a twelve months period, and at least one relevant asthma therapy 
prescription during the following twelve months period. Disease-related and all-
cause related medical costs, drug costs, and hospitalization risk were measured. 
These measures were modeled at varying levels of medication adherence using 
regression analysis. Adherence (Sokol, 2005) was defined as the percentage of days 
during the analysis period that patients had a supply of 1 or more maintenance 
medications for the condition. The days of supply are calculated based on WHO 
DDD’s. This measurement strategy reduces the risk of overestimating adherence. 
For prescriptions extending beyond the end of the analysis period, days’ supply is 
truncated at the end of the period. Patients in each study sample are stratified into 
5 categories based on their adherence score: 1–19%, 20–39%, 40–59%, 60–79%, or 
80–100 %. Results: High level of medication adherence was associated with lower 
hospitalization and exacerbation rates. ConClusions: Increased drug utilization 
can provide a net economic return when it is driven by improved adherence.
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tion and costs of the patients with COPD in Hungary. Methods: The authors con-
ducted a retrospective observation of the patients continuously enrolled in medical 
and prescription benefit plans from July 2007 to June 2012. The study is based on 
patient attendance data of Hungarian National Health Insurance Fund - NHIFA. 
The accessible resource uniquely contains the detailed provision data (medicine, 
out- and inpatient services) about the whole 10 millions Hungarian populations. 
Inclusion criterion for the patients was at least one diagnosis of COPD in inpatient 
or outpatient care (ICD code J44) and at least one relevant COPD therapy prescrip-
tion in a twelve months period, and at least one relevant COPD therapy prescription 
during the following twelve months period. Disease-related and all-cause related 
medical costs, drug costs, and hospitalization risk were measured. These measures 
were modeled at varying levels of medication adherence using regression analysis. 
Adherence (Sokol, 2005) was defined as the percentage of days during the analysis 
period that patients had a supply of 1 or more maintenance medications for the con-
dition. The days of supply are calculated based on WHO DDD’s. This measurement 
